These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model. Grossman I; Kolitz S; Komlosh A; Zeskind B; Weinstein V; Laifenfeld D; Gilbert A; Bar-Ilan O; Fowler KD; Hasson T; Konya A; Wells-Knecht K; Loupe P; Melamed-Gal S; Molotsky T; Krispin R; Papir G; Sahly Y; Hayden MR Ann N Y Acad Sci; 2017 Nov; 1407(1):75-89. PubMed ID: 29168242 [TBL] [Abstract][Full Text] [Related]
6. Two decades of glatiramer acetate: From initial discovery to the current development of generics. Weinstock-Guttman B; Nair KV; Glajch JL; Ganguly TC; Kantor D J Neurol Sci; 2017 May; 376():255-259. PubMed ID: 28431621 [TBL] [Abstract][Full Text] [Related]
8. Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate. D Alessandro J; Garofalo K; Zhao G; Honan C; Duffner J; Capila I; Fier I; Kaundinya G; Kantor D; Ganguly T CNS Neurol Disord Drug Targets; 2017; 16(6):714-723. PubMed ID: 28240190 [TBL] [Abstract][Full Text] [Related]
9. An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate. Erzina D; Capecchi A; Javor S; Reymond JL Angew Chem Int Ed Engl; 2021 Dec; 60(50):26403-26408. PubMed ID: 34618395 [TBL] [Abstract][Full Text] [Related]
10. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F; JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034 [TBL] [Abstract][Full Text] [Related]
11. Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. Selmaj K; Barkhof F; Belova AN; Wolf C; van den Tweel ER; Oberyé JJ; Mulder R; Egging DF; Koper NP; Cohen JA; Mult Scler; 2017 Dec; 23(14):1909-1917. PubMed ID: 28090798 [TBL] [Abstract][Full Text] [Related]
12. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial. Ehling R; Di Pauli F; Lackner P; Rainer C; Kraus V; Hegen H; Lutterotti A; Kuenz B; De Zordo T; Schocke M; Glatzl S; Löscher WN; Deisenhammer F; Reindl M; Berger T J Neuroimmunol; 2015 Oct; 287():98-105. PubMed ID: 26439969 [TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate increases T- and B -regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis. Aharoni R; Eilam R; Schottlender N; Radomir L; Leistner-Segal S; Feferman T; Hirsch D; Sela M; Arnon R J Neuroimmunol; 2020 Aug; 345():577281. PubMed ID: 32534388 [TBL] [Abstract][Full Text] [Related]
14. Improvement of motor conduction velocity in hereditary neuropathy of LAMA2-CMD dy Rabie M; Yanay N; Fellig Y; Konikov-Rozenman J; Nevo Y Clin Neurophysiol; 2019 Oct; 130(10):1988-1994. PubMed ID: 31476705 [TBL] [Abstract][Full Text] [Related]
15. Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis. Bourdette D; Hartung D JAMA Neurol; 2015 Dec; 72(12):1411-3. PubMed ID: 26457848 [No Abstract] [Full Text] [Related]
16. Comparison of Copaxone Arends RJ; Wang D; Buurman M; Luten J; Koper NP; Wolf C; Scheren M Pharmazie; 2019 Aug; 74(8):449-461. PubMed ID: 31526436 [TBL] [Abstract][Full Text] [Related]
17. Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes. Borchard G; Crommelin DJA Expert Opin Drug Deliv; 2018 Mar; 15(3):247-259. PubMed ID: 29241378 [TBL] [Abstract][Full Text] [Related]
19. Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update. Johnson KP Expert Opin Drug Metab Toxicol; 2010 May; 6(5):643-60. PubMed ID: 20397968 [TBL] [Abstract][Full Text] [Related]
20. Gut microbiota in multiple sclerosis: possible influence of immunomodulators. Cantarel BL; Waubant E; Chehoud C; Kuczynski J; DeSantis TZ; Warrington J; Venkatesan A; Fraser CM; Mowry EM J Investig Med; 2015 Jun; 63(5):729-34. PubMed ID: 25775034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]